Drug Profile
Pegfilgrastim biosimilar - Dong-A ST
Alternative Names: DA-3031; Dulastin; PEG-filgrastim - Dong-A; PEG-G-CSF - Dong-A; Pegfilgrastim biosimilar - Dong-A; Pegylated-G-CSF - Dong-A; Tripegfilgrastim; Tripegfilgrastim - Dong-ALatest Information Update: 25 Nov 2021
Price :
$50
*
At a glance
- Originator Dong-A Pharmaceutical
- Developer Dong-A ST
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Proteins; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Neutropenia
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Neutropenia(In adolescents, In children, Chemotherapy-induced) in South Korea (SC, Injection)
- 01 Nov 2018 Dong-A completes a phase I trial in Neutropenia (In children, In adolescents, Chemotherapy-induced) in South Korea (SC) (NCT02963389)
- 01 Sep 2016 Phase-I clinical trials in Neutropenia (In children, In adolescents, Chemotherapy-induced) in South Korea (SC) (NCT02963389)